HiveWatch’s Post

A few of the potential benefits of microneedle: -rapid uptake of drug into the body, faster than IM/sub-Q -no needle -at home administration -room temperature storage Kindeva has commercial manufacturing capabilities. This webinar is a good start to understanding the developments in MAP.

We’re thrilled to join the Anticoagulation Forum’s Corporate Council!   At Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), we are proud to align with the Anticoagulation Forum (AC Forum). With 15,000 healthcare professional members, AC Forum is the largest organization dedicated to advancing anticoagulation care globally.  Our participation reflects our shared commitment to innovation, educational initiatives, and improving patient outcomes.   With our development of tecarfarin, a new vitamin K antagonist (VKA), we aim to address gaps in chronic anticoagulation therapy and provide a superior and safer option for patients with left ventricular assist devices or rare cardiovascular conditions.    We look forward to collaborating with the AC Forum’s thought leaders and contributing to initiatives that share research findings, promote best practices and advance patient outcomes.   #HealthcareInnovation #Anticoagulation #ACForum #Pharma #PatientOutcomes #CadrenalTherapeutics #LVAD 

Exciting News for Nuclear Medicine! A new rule proposes to unbundle diagnostic radiopharmaceuticals from the current payment system, classifying them separately from "supplies." This will prevent CMS from overpaying for low-cost diagnostics and offer patients access to advanced imaging agents. #nuclearmedicine #radiologynews #healthcare #compuraymedical

We’re thrilled to join the Anticoagulation Forum’s Corporate Council!   At Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), we are proud to align with the Anticoagulation Forum (AC Forum). With 15,000 healthcare professional members, AC Forum is the largest organization dedicated to advancing anticoagulation care globally.  Our participation reflects our shared commitment to innovation, educational initiatives, and improving patient outcomes.   With our development of tecarfarin, a new vitamin K antagonist (VKA), we aim to address gaps in chronic anticoagulation therapy and provide a superior and safer option for patients with left ventricular assist devices or rare cardiovascular conditions.    We look forward to collaborating with the AC Forum’s thought leaders and contributing to initiatives that share research findings, promote best practices and advance patient outcomes.   #HealthcareInnovation #Anticoagulation #ACForum #Pharma #PatientOutcomes #CadrenalTherapeutics #LVAD 

We’re thrilled to join the Anticoagulation Forum’s Corporate Council!   At Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), we are proud to align with the Anticoagulation Forum (AC Forum). With 15,000 healthcare professional members, AC Forum is the largest organization dedicated to advancing anticoagulation care globally. Our participation reflects our shared commitment to innovation, educational initiatives, and improving patient outcomes.   With our development of tecarfarin, a new vitamin K antagonist (VKA), we aim to address gaps in chronic anticoagulation therapy and provide a superior and safer option for patients with left ventricular assist devices or rare cardiovascular conditions.    We look forward to collaborating with the AC Forum’s thought leaders and contributing to initiatives that share research findings, promote best practices and advance patient outcomes.   #HealthcareInnovation #Anticoagulation #ACForum #Pharma #PatientOutcomes #CadrenalTherapeutics #LVAD 

BMS is poised to enter the Eosinophilic Esophagitis (EoE) market. Buried in the BMS Q2 2024 earnings call was news that company's eosinophilic esophagitis (EoE) treatment, cendakimab, successfully met Phase 3 clinical endpoints. Similar to already-approved, Dupixent, cendakimab is a biologic with subcutaneous injections every other week. Specifics on the data have yet to be released, this new agent could pose some competitive pressure for Dupixent in EoE. #gastroenterology #clinicaldata https://lnkd.in/g_2a2MWv

Today Liquidia Corporation announced that it has filed litigation challenging the FDA’s decision to grant clinical investigation exclusivity to a competing product. This follows the tentative approval of YUTREPIA for the treatment of adults with PAH and PH-ILD. Dr. Roger Jeffs, Ph.D., Chief Executive Officer of Liquidia, said: “The FDA’s action improperly allows United Therapeutics to tack on yet another regulatory exclusivity, stifling competition and patient choice. This decision violates clear congressional intent to allow NCI exclusivity only for true innovations that are supported by new clinical studies that demonstrate safety and/or efficacy of the innovation. It is our strong belief that the FDA’s decision to grant Tyvaso DPI this new NCI exclusivity should be vacated, and Liquidia should be allowed to bring YUTREPIA to market for the benefit of patients immediately.” Read more here: https://bit.ly/4fTP1U2

Make use of our experts on patient recruitment and feasibility at the Nordic Life Science Days in Malmö next week!   On 18-19 September, Simon Klaasen and Ola Hasselgren will be there, ready to share their expertise in patient recruitment and feasibility studies. Whether you’re in the early stages of planning a clinical study or already writing your protocol, stop by our booth to explore how we can help boost your recruitment efforts.   Did you know? Our patient feasibility studies can provide crucial patient feedback before you even begin. By incorporating patient insights early, you can optimize your study and reduce the overall budget—saving time and resources while increasing your study’s success rate.   Don’t miss this opportunity to meet with us at NLSDays! Let’s discuss how we can make your next clinical trial more efficient and patient-focused.   Visit us at our stand or learn more at www.link2trials.com . Follow us!   #NLSDays #PatientRecruitment #ClinicalTrials #FeasibilityStudies #CRO #Pharma #MedTech #InvestInPatients #NordicStars #ClinicalExcellence #Link2Trials

Time to comment has started! Let’s do this! Long time coming, and significant amount of lobbying to get us to this point. Kudos!! 🤞🤞🤞🤞🤞🤞🤞🤞🤞 #radiopharmaceuticals #nuclearmedicine #theranostics #radioligandtherapy #radiology #precisionmedicine

If you are attending SCOPE stop by and learn how AliveCor's Kardia devices can optimize your clinical resarch studies!